Compare Wockhardt with Biocon Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT vs BIOCON - Comparison Results

WOCKHARDT     Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

BIOCON  
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WOCKHARDT BIOCON WOCKHARDT/
BIOCON
 
P/E (TTM) x -55.5 31.5 - View Chart
P/BV x 1.2 4.1 30.3% View Chart
Dividend Yield % 0.0 0.2 1.3%  

Financials

 WOCKHARDT   BIOCON
EQUITY SHARE DATA
    WOCKHARDT
Mar-18
BIOCON
Mar-19
WOCKHARDT/
BIOCON
5-Yr Chart
Click to enlarge
High Rs1,012707 143.1%   
Low Rs532554 96.0%   
Sales per share (Unadj.) Rs355.991.9 387.2%  
Earnings per share (Unadj.) Rs-60.316.7 -360.7%  
Cash flow per share (Unadj.) Rs-46.824.2 -193.4%  
Dividends per share (Unadj.) Rs0.011.00 1.0%  
Dividend yield (eoy) %00.2 0.8%  
Book value per share (Unadj.) Rs257.8101.6 253.7%  
Shares outstanding (eoy) m110.63600.00 18.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.26.9 31.6%   
Avg P/E ratio x-12.837.7 -33.9%  
P/CF ratio (eoy) x-16.526.1 -63.3%  
Price / Book Value ratio x3.06.2 48.2%  
Dividend payout %06.0 -0.3%   
Avg Mkt Cap Rs m85,379378,330 22.6%   
No. of employees `0006.36.1 102.0%   
Total wages/salary Rs m9,37111,653 80.4%   
Avg. sales/employee Rs Th6,295.08,994.3 70.0%   
Avg. wages/employee Rs Th1,498.31,900.7 78.8%   
Avg. net profit/employee Rs Th-1,066.31,635.3 -65.2%   
INCOME DATA
Net Sales Rs m39,36955,144 71.4%  
Other income Rs m1,2021,444 83.3%   
Total revenues Rs m40,57156,588 71.7%   
Gross profit Rs m1815,883 0.1%  
Depreciation Rs m1,4954,478 33.4%   
Interest Rs m2,555709 360.4%   
Profit before tax Rs m-2,83012,140 -23.3%   
Minority Interest Rs m09 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-3,5820-   
Tax Rs m2572,123 12.1%   
Profit after tax Rs m-6,66910,026 -66.5%  
Gross profit margin %028.8 0.2%  
Effective tax rate %-9.117.5 -51.9%   
Net profit margin %-16.918.2 -93.2%  
BALANCE SHEET DATA
Current assets Rs m33,79648,228 70.1%   
Current liabilities Rs m26,91730,376 88.6%   
Net working cap to sales %17.532.4 54.0%  
Current ratio x1.31.6 79.1%  
Inventory Days Days7968 116.2%  
Debtors Days Days8986 104.4%  
Net fixed assets Rs m39,66464,130 61.8%   
Share capital Rs m5533,000 18.4%   
"Free" reserves Rs m27,96857,980 48.2%   
Net worth Rs m28,52260,980 46.8%   
Long term debt Rs m21,73115,766 137.8%   
Total assets Rs m81,620121,924 66.9%  
Interest coverage x-0.118.1 -0.6%   
Debt to equity ratio x0.80.3 294.7%  
Sales to assets ratio x0.50.5 106.6%   
Return on assets %-5.08.8 -57.2%  
Return on equity %-23.416.4 -142.2%  
Return on capital %-7.716.8 -45.8%  
Exports to sales %028.1 0.0%   
Imports to sales %018.9 0.0%   
Exports (fob) Rs mNA15,506 0.0%   
Imports (cif) Rs mNA10,399 0.0%   
Fx inflow Rs m9,80715,506 63.2%   
Fx outflow Rs m1,78910,399 17.2%   
Net fx Rs m8,0195,107 157.0%   
CASH FLOW
From Operations Rs m68411,546 5.9%  
From Investments Rs m6,302-7,138 -88.3%  
From Financial Activity Rs m-7,695-2,417 318.4%  
Net Cashflow Rs m-6642,103 -31.6%  

Share Holding

Indian Promoters % 74.5 40.4 184.4%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 2.3 8.4 27.4%  
FIIs % 7.7 10.7 72.0%  
ADR/GDR % 0.1 0.0 -  
Free float % 15.4 19.9 77.4%  
Shareholders   67,757 109,995 61.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WOCKHARDT With:   UNICHEM LAB  AUROBINDO PHARMA  IPCA LABS  GLENMARK PHARMA  SUN PHARMA  

Compare WOCKHARDT With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 142 Points Higher; Healthcare and Capital Goods Stocks Witness Buying(Closing)

Extending gains to the third straight day, Indian share markets witnessed buying interest throughout the day today, amid sustained foreign fund inflows and positive cues from global markets.

Related Views on News

WOCKHARDT Announces Quarterly Results (3QFY20); Net Profit Up 125.0% (Quarterly Result Update)

Jan 28, 2020 | Updated on Jan 28, 2020

For the quarter ended December 2019, WOCKHARDT has posted a net profit of Rs 192 m (up 125.0% YoY). Sales on the other hand came in at Rs 9 bn (down 16.9% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

BIOCON Announces Quarterly Results (3QFY20); Net Profit Up 1.2% (Quarterly Result Update)

Jan 24, 2020 | Updated on Jan 24, 2020

For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY20); Net Profit Down 30.5% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

WOCKHARDT Announces Quarterly Results (1QFY20); Net Profit Up 57.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, WOCKHARDT has posted a net profit of Rs 369 m (up 57.2% YoY). Sales on the other hand came in at Rs 9 bn (down 14.3% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

More Views on News

Most Popular

These 5 Smallcaps Deserve a Place in Your Coffee Can Portfolio(Profit Hunter)

Jul 28, 2020

When it comes to quality stocks, doing less is more.

Before You Buy Your First Electric Vehicle Consider Buying this Stock(Profit Hunter)

Jul 29, 2020

As competition intensifies in the electric vehicle space, only few will create huge wealth over the years.

Large Opportunities Are Coming Our Way

Aug 5, 2020

Kenneth Andrade tells us why stocks will bounce back strongly and what he's bullish on.

How to Buy Stocks at 50% Off(Fast Profits Daily)

Aug 7, 2020

In this video I'll show you how to enter into a long trade at the right price.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT SHARE PRICE


Aug 10, 2020 (Close)

TRACK WOCKHARDT

  • Track your investment in WOCKHARDT with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE WOCKHARDT WITH

MARKET STATS